Skandinaviska Enskilda Banken AB publ Purchases 9,668 Shares of DexCom, Inc. (NASDAQ:DXCM)

Skandinaviska Enskilda Banken AB publ increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 283,654 shares of the medical device company's stock after buying an additional 9,668 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.07% of DexCom worth $22,114,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Blue Whale Capital LLP increased its holdings in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock worth $15,821,000 after purchasing an additional 113,000 shares in the last quarter. Brooktree Capital Management bought a new position in shares of DexCom in the third quarter valued at approximately $683,000. Motley Fool Asset Management LLC lifted its holdings in shares of DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock valued at $17,993,000 after purchasing an additional 171,150 shares in the last quarter. Watts Gwilliam & Co. LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $3,334,000. Finally, Congress Asset Management Co. lifted its holdings in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Remove Ads

DexCom Stock Performance

Shares of DexCom stock traded down $0.65 during trading hours on Tuesday, reaching $70.70. The company had a trading volume of 2,603,968 shares, compared to its average volume of 3,875,814. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business has a fifty day simple moving average of $83.82 and a 200 day simple moving average of $76.94. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market cap of $27.63 billion, a PE ratio of 49.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,657 shares of company stock valued at $8,019,422 over the last three months. Company insiders own 0.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DXCM. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and raised their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.